Role of inflammation in intractable temporal lobe epilepsy

A Thesis submitted for partial fulfillment of MD, Degree in Neurology By

Salem Taha El sayed

M.B.B.Ch., M. Sc. Ain Shams University

Supervised by

Prof. Mohamad Ossama Abdulghani

Professor of Neurology Faculty of Medicine Ain-Shams University

Prof. Taha Kamel Taha

Professor of Neurology Faculty of Medicine Ain-Shams University

Prof. Ayman Mohamed Nassef

Professor of Neurology Faculty of Medicine Ain-Shams University

Dr. Haytham Mohamed Hamdy

Lecturer of Neurology
Faculty of Medicine Ain-Shams University

Faculty of Medicine Ain-Shams University CAIRO, 2014

بسم الله الرحمن الرحيم

ا قالوا سبحانك لا علم لنا الحكيم إلا ما علم إذا إذا أنت العليم الحكيم

حدق الله العظيم سورة البقرة

ACKNOWLEDGEMENT

First and foremost, I feel always indebted to **Allah** the most kind and most merciful, as we owe to him for his great care and guidance in every step in our life, and who enabled me to accomplish this work.

I wish to express my greatest gratitude and ultimate thanks to **Prof. Mohamad Ossama Abdulghani** Professor of Neurology, Faculty of Medicine, Ain Shams University for accepting to supervise this work and for his valuable supervision and guiding comments. He generously devoted much of his precious time and provided unlimited in depth guidance, I sincerely appreciate all the encouragement and support given by him.

I am profoundly grateful to **Prof. Taha Kamel**, Professor of Neurology, Faculty of medicine, Ain Shams University, for his close and kind supervision, his constant fatherly advice and support and scientific guidance, for his trust in my performance and my work.

[Type text]

Acknowledgement

I am deeply grateful to **Prof. Ayman Nassef**, Professor of Neurology, Faculty of Medicine, Ain Shams University, I am grateful for his helpful notes and valuable recommendations throughout this work. His constant guidance helped me to achieve this work.

To **Dr. Haytham Hamdy**, Lecturer of Neurology, Faculty of Medicine, Ain Shams University, I express my sincere appreciation for his patient guidance, constructive remarks and continuous support. He gave genuine and kind help to achieve the best of this work.

I would like to express my appreciation to Madam Mona Adly and Mr. Emad Hossam, the technicians in El Demerdash Pathology department for helping me storing samples and conducting the test. Also, my appreciation to Mrs. Rasha Mohamed the epilepsy clinic nurse for helping me in collecting the blood samples from selected patients.

I would like to extend my thanks to all my professors, colleagues and friends, so many of them influenced, encouraged and inspired me throughout the years.

[Type text]

Acknowledgement

Last but not least, I wish to express my love and respect to my parents, my wife, my lovely sons and my brother, for your endless love and care, for your valuable emotional support and continuous encouragement which brought the best out of me. I owe you all every achievement throughout my life.

Finally, my thanks should go to all the patients who were the subjects of this work and who cooperated in this research.

List of Tables

| | | Page |
|----------|--|-----------|
| Table 1 | Mechanisms of glia-mediated neuronal | 37 |
| | hyperexcitability Cellular component Change | |
| | in epilepsy Functional effect | |
| Table 2 | Role of different cytokines and growth factors | 67 |
| | in seizure susceptibility | |
| Table 3 | Combination of various AEDs in Group A | 89 |
| | patients | |
| Table 4 | Comparison between refractory TLE, | 94 |
| | controlled TLE and healthy volunteers | |
| | regarding sample characteristics | |
| Table 5 | Baseline IL-6 with the duration of illness in | 96 |
| | Group A patients | |
| Table 6 | Postictal IL-6 and seizure frequency in Group | 98 |
| | A patients | |
| Table 7 | Baseline IL-6 and EEG finding in Group A | 100 |
| | patients | |
| Table 8 | Postictal IL-6 and EEG finding in Group A | 100 |
| | patients | |
| Table 9 | Baseline and postictal IL-6 with past history of | 101 |
| | SE in Group A patients | |
| Table 10 | Baseline IL-6 and duration of illness in Group | 102 |
| | B patients | |
| Table 11 | Baseline IL-6 and seizure frequency in Group | 103 |
| | B patients | |
| Table 12 | Baseline IL-6 with EEG finding in Group B | 105 |
| | patients | |
| Table 13 | Each single AED with baseline IL-6 in Group | 105 |
| | B patients | |
| Table 14 | AEDs compared to each others as regards | 106 |
| | baseline IL-6 in Group B patients | |
| Table 15 | Baseline IL-6 among all groups | 107 |

| | | Page |
|----------|--|------|
| Table 16 | Baseline IL-6 among the two groups of patients | 107 |
| Table 17 | Baseline and Postictal IL-6 among patient groups | 108 |
| Table 18 | Baseline IL-6 and the duration of illness among patient groups | 109 |
| Table 19 | Baseline IL-6 and seizure frequency patient groups | 110 |
| Table 20 | Baseline IL-6 and seizure semiology patient groups | 110 |
| Table 21 | Baseline IL-6 and EEG finding patient groups | 111 |
| Table 22 | Semiological seizure classification | 175 |

List of Figures

| | | Page |
|-----------|--|-----------|
| Figure 1 | Cuniform tablet Circa 700Bc | 4 |
| Figure 2 | Epilepsy " nsjt" as written in the Papyrus in ancient Egypt | 6 |
| Figure 3 | Peiter Breugal The Elder 'The Epileptic Women of Molenbeek' C1560 | 7 |
| Figure 4 | Hughlings Jackson | 8 |
| Figure 5 | Hippocampal structure and connections | 11 |
| Figure 6 | PDS of the neuron membrane potential. | 26 |
| Figure 7 | Mechanism of action of glutamate on neurons and glial cells. | 30 |
| Figure 8 | T cell migration in epilepsy. | 33 |
| Figure 9 | Schematic representation of the cerebral vasculature and CSF circulation and their relation to inflammatory mediators and antigen transport. | 34 |
| Figure 10 | Role of astrocytes and microglia in inflammation and excitability | 36 |
| Figure 11 | Pathophysiological cascade of inflammatory events in epilepsy | 49 |
| Figure 12 | The structure of P-glycoprotein | 72 |
| Figure 13 | Simple strategy for choosing AEDs as adjunctive therapy in patients with refractory partial seizures. | 76 |
| Figure 14 | Curative and palliative surgery for epilepsy | 78 |
| Figure 15 | VNS | 79 |
| Figure 16 | The vagus nerve and the nicotinic anti- inflammatory pathway | 80 |
| Figure 17 | Seizure semiology in Group A patients | 89 |
| Figure 18 | Seizure semiology in Group B patients | 92 |

| Figure 19 | Postictal and baseline IL-6 in refractory TLE | 95 |
|-----------|--|-----|
| Figure 20 | Baseline IL 6 and seizure frequency | 97 |
| Figure 21 | Baseline IL 6 and seizure semiology in Group A patients | 98 |
| Figure 22 | Postictal IL-6 and seizure semiology in Group A patients | 99 |
| Figure 23 | Baseline IL-6 with seizure semiology in Group B patients | 104 |
| Figure 24 | Baseline IL-6 among patient groups | 107 |
| Figure 25 | Mean baseline and postictal IL-6 and gender of patients | 109 |

Table of content

| TABLE OF CONTENTS | |
|---|------|
| | Page |
| List of tables | i |
| List of figures | iii |
| List of abbreviations | V |
| Introduction and Aim of the Work | 1 |
| Review of Literature | |
| Chapter (1): Historical Background | 4 |
| Chapter (2): Epileptogenesis and Neurogenesis | 9 |
| Chapter (3): Epilepsy and Inflammation | 41 |
| Chapter (4): Refractory Epilepsy | 70 |
| Subjects an Methods | 82 |
| Results | 86 |
| Discussion | 112 |
| Conclusion | 123 |
| Recommendations | 126 |
| Summary | 127 |
| References | 130 |
| Appendix | 157 |
| Arabic Summary | ١ |

List of Abbreviations

| 5-HT | 5-hydroxyl triptamine |
|-----------------|---|
| ACH | Acetylcholine |
| ACTH | Adrenocorticotropic hormone |
| AED | Antiepileptic drug |
| AMPA | α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic |
| | acid |
| AP | Action potentials |
| APCs | Antigen presenting cells |
| AQP 4 | Aquaporin 4 |
| BBB | Blood-brain barrier |
| BDNF | Brain-derived neurotrophic factor |
| Ca^{2+} | Calcium |
| cAMP | Cyclic adenosine monophosphate |
| CBZ | Carbamazepine |
| Cl ⁻ | Chloride |
| COX-2 | Cyclooxygenase-2 |
| CSF | Cerebrospinal fluid |
| DE | Dentate gyrus |
| EAAT | Excitatory amino acid transporter |
| EEG | Electroencephalogram |
| ENT1/2 | Equilibrative nucleoside transporters 1 and 2 |
| EPSP | Excitatory postsynaptic potential |
| FGF | Fibroblast growth factor |
| FS | Febrile seizure |
| FSE | Febrile status epilepticus |
| GABA | Gamma-aminobutyric acid |
| GCD | Granule cell dispersion |
| GFAP | Glial fibrillary acidic protein |
| HMGB1 | High mobility group box 1 |
| HPA | Hypothalamic—pituitary—adrenal |
| I-Cam | Intercellular Adhesion Molecule |

| ICE | Interleukin Converting Enzyme |
|-----------------|--|
| IFNs | Interferons |
| IGF | Insulin growth factor |
| IL | Interleukin |
| ILAE | International League Against Epilepsy |
| IPSP | Inhibitory postsynaptic potential |
| IS | Infantile spasms |
| K^+ | Potassium |
| KCNQ | Potassium Channel, Voltage-Gated, KQT-like |
| T7' 4 1 | subfamily |
| Kir4.1 | Rectifying K ⁺ channels |
| LEC | Lateral entorhinal cortex |
| MCD | Malformation of cortical development |
| MCP-1 | Monocyte chemoattractant protein-1 |
| M-CSF | Macrophage colony stimulating factor |
| MDR1 | Multiple drug resistance 1 |
| MEC | Medial entorhinal cortex |
| MFS | Mossy fiber sprouting |
| MMP | Matrix metalloproteinases |
| MTS | Mesial Temporal sclerosis |
| MRP | Multidrug resistance protein |
| Na ⁺ | Sodium |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated |
| | B cells |
| NMDA | N-methyl-D-aspartate |
| NO | Nitric oxide |
| OPC | Outpatient clinic |
| PAF | Platelet activating factor |
| PDS | Paroxysmal depolarising shift |
| PGE2 | Prostaglandin E2 |
| P-gp | P-glycoprotein |
| PTZ | Pentylentetrazole |

List of Abbreviations

| RMP | Resting membrane potential |
|-------|--|
| SAH | Selective amygdalohippocampectomy |
| sATR | Standardized anterior temporal resection |
| SE | Status epilepticus |
| SSC | Semiological seizure classification |
| TBI | Traumatic brain injury |
| TGF-β | Transforming growth factor- β |
| TLE | Temporal lobe epilepsy |
| TLR | Toll-like receptor |
| TNF | Tumor necrosis factor |
| VNS | Vagal nerve stimulation |
| V-Cam | Vascular cell adhesion protein |
| VEGF | Vascular endothelial growth factor |
| VPA | Valproic acid |

Introduction

Epilepsy is a clinically heterogeneous group of disorders; defined as spontaneous occurrence of seizures associated with electric discharges of the brain. Its prevalence is 5-10/1000, 25-30% of patients have intractable epilepsy, epileptic seizures result from excessive discharge in a population of hyper excitable neurons. Most epileptic seizures are due to discharges generated in cortical and hippocampal structures, although subcortical structures are also involved in some seizures types (**Brodie and Kwan, 2002**).

Variety of factors influence the incidence and prevalence of seizures. Reports suggest higher incidence of seizures among patients with chronic inflammatory problems compared to normal population (Rao et al, 2009).

Recent findings suggest involvement of inflammation in the pathogenesis and the course of epilepsy through cytokines and other pro inflammatory mediators which includes interleukins, interferons, tumor necrosis factors, chemokines and growth factors, the significance of cytokine production in relation to epileptic seizures is not yet fully known as Interleukin (IL)-1 β and Interleukin (IL)-6 have been shown to exert neuroprotective and neurotrophic effects (**Vezzani and Granata, 2005**).

Some cytokines act to make disease worse (proinflammatory), whereas others serve to reduce inflammation and promote healing (anti-inflammatory). Proinflammatory cytokines are harmful to the host, particularly during overwhelming infection. IL-1 and tumor necrosis factor (TNF) are proinflammatory cytokines, and when they are administered to humans, they produce fever, inflammation, tissue destruction, and, in some cases, shock and death. Blocking IL-1 or TNF has been highly successful in some

Introduction, Historical background (chapter I)

diseases such as rheumatoid arthritis, inflammatory bowel disease, or graft-vs-host disease (Dinarello, 2000).

Major anti-inflammatory cytokines include IL-1 receptor antagonist, IL-4, IL-6, IL-10, IL-11, and IL-13. The functional definition of an anti-inflammatory cytokine is the ability of the cytokine to inhibit the synthesis of IL-1 and TNF. IL-6 has both proinflammatory and anti-inflammatory properties. Although IL-6 act predominantly as an anti-inflammatory cytokine (**Steven and DePalo, 2000**).

Experimental evidence in rodent models has demonstrated that seizures induce high levels of inflammatory mediators in brain regions involved in the generation and propagation of epileptic activity. This response consists of an increase in prototypic inflammatory cytokines such as interleukin1 β , IL-6 and TNF- α in microglia and astrocytes, which is accompanied, and often followed, by a cascade of down-stream inflammatory events (i.e. activation of Nuclear factor-kB, complement system, chemokines, acute phase proteins) (Vezzani and Granata, 2005).